FI960743A0 - Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin - Google Patents

Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin

Info

Publication number
FI960743A0
FI960743A0 FI960743A FI960743A FI960743A0 FI 960743 A0 FI960743 A0 FI 960743A0 FI 960743 A FI960743 A FI 960743A FI 960743 A FI960743 A FI 960743A FI 960743 A0 FI960743 A0 FI 960743A0
Authority
FI
Finland
Prior art keywords
hek
bind
polypeptides
receptor
cell surface
Prior art date
Application number
FI960743A
Other languages
English (en)
Swedish (sv)
Other versions
FI960743A (fi
Inventor
Mary Patricia Beckmann
Douglas Pat Cerretti
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI960743A0 publication Critical patent/FI960743A0/fi
Publication of FI960743A publication Critical patent/FI960743A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
FI960743A 1993-08-20 1996-02-19 Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin FI960743A (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10974593A 1993-08-20 1993-08-20
US11442693A 1993-08-30 1993-08-30
US16113293A 1993-12-03 1993-12-03
US08/240,124 US5516658A (en) 1993-08-20 1994-05-09 DNA encoding cytokines that bind the cell surface receptor hek
PCT/US1994/009282 WO1995006065A1 (en) 1993-08-20 1994-08-17 Cytokines that bind the cell surface receptor hek

Publications (2)

Publication Number Publication Date
FI960743A0 true FI960743A0 (fi) 1996-02-19
FI960743A FI960743A (fi) 1996-02-19

Family

ID=27493708

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960743A FI960743A (fi) 1993-08-20 1996-02-19 Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin

Country Status (15)

Country Link
US (5) US5516658A (fi)
EP (1) EP0804482B1 (fi)
JP (2) JP3699477B2 (fi)
KR (1) KR960704038A (fi)
AT (1) ATE259377T1 (fi)
AU (1) AU680540B2 (fi)
CA (1) CA2169851A1 (fi)
DE (1) DE69433552T2 (fi)
DK (1) DK0804482T3 (fi)
ES (1) ES2216000T3 (fi)
FI (1) FI960743A (fi)
NO (1) NO960652L (fi)
NZ (1) NZ271878A (fi)
PT (1) PT804482E (fi)
WO (1) WO1995006065A1 (fi)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669960B2 (en) * 1992-11-13 1996-06-27 Immunex Corporation Novel cytokine designated elk ligand
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
ATE232901T1 (de) * 1994-04-04 2003-03-15 Regeneron Pharma Biologisch aktive ligande der eph familie
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
USRE37582E1 (en) 1994-10-05 2002-03-12 Immunex Corporation Cytokine designated LERK-6
US5919905A (en) * 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
DK0785716T3 (da) 1994-10-05 2007-04-02 Immunex Corp Cytokin betegnet LERK-6
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
AUPO754997A0 (en) * 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
US20030198951A1 (en) * 1999-12-02 2003-10-23 David Mack Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2001083703A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Checkpoint-activating oligonucleotides
US20030092035A1 (en) * 2000-05-04 2003-05-15 Anderson David J. Pain signaling molecules
AU2002249521B2 (en) * 2001-01-16 2007-06-21 Serono Genetics Institute S.A. Discriminative nucleic acid analysis using clone sequence signatures
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1553963A4 (en) * 2002-09-24 2006-05-03 Burnham Inst NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY
CA2522082A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US8609090B2 (en) 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
DE602005014650D1 (de) * 2004-07-27 2009-07-09 Riken Vektor zur expression von humaner n-deacetylase/n-sulfotransferase 2
EP1841790B1 (en) * 2005-01-27 2010-11-03 The Burnham Institute Ephb receptor-binding peptides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US9223751B2 (en) * 2006-09-22 2015-12-29 Intel Corporation Performing rounding operations responsive to an instruction
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EA023555B1 (ru) 2007-08-21 2016-06-30 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
TWI585106B (zh) 2010-12-08 2017-06-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
EP3426297A4 (en) 2016-03-08 2019-08-14 Janssen Biotech, Inc. GITR ANTIBODIES, METHODS AND USES
US10532042B2 (en) 2016-12-22 2020-01-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
JP7360396B2 (ja) 2018-06-01 2023-10-12 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
CA3099799A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MX2021005700A (es) 2018-11-19 2021-07-07 Amgen Inc Inhibidores de kras g12c y metodos de uso de los mismos.
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US20220056015A1 (en) 2018-12-20 2022-02-24 Amgen Inc. Kif18a inhibitors
EP3898592B1 (en) 2018-12-20 2024-10-09 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
AU2020280024A1 (en) 2019-05-21 2021-12-09 Amgen Inc. Solid state forms
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
EP4007756A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
EP4051266A1 (en) 2019-10-31 2022-09-07 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2022553857A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
KR20220100903A (ko) 2019-11-08 2022-07-18 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
US20230255972A1 (en) 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
MX2023013084A (es) 2021-05-05 2023-11-17 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer.
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094134A1 (en) * 1990-10-16 1992-04-17 Vishva M. Dixit Cytokine-induced marker for inflammatory response
JPH04224527A (ja) * 1990-12-25 1992-08-13 Daikin Ind Ltd ペンタフルオロジクロロプロパンの製造方法
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
WO1993000425A1 (en) * 1991-06-21 1993-01-07 Amrad Corporation Limited A novel receptor-type tyrosine kinase and use thereof
AU669960B2 (en) * 1992-11-13 1996-06-27 Immunex Corporation Novel cytokine designated elk ligand
IL107599A0 (en) * 1992-11-13 1994-02-27 Amgen Inc Eck receptor ligands
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek

Also Published As

Publication number Publication date
US5738844A (en) 1998-04-14
US5969110A (en) 1999-10-19
EP0804482A4 (en) 2001-05-16
EP0804482B1 (en) 2004-02-11
JP3786944B2 (ja) 2006-06-21
AU680540B2 (en) 1997-07-31
ES2216000T3 (es) 2004-10-16
PT804482E (pt) 2004-06-30
DK0804482T3 (da) 2004-06-07
CA2169851A1 (en) 1995-03-02
US6274117B1 (en) 2001-08-14
EP0804482A1 (en) 1997-11-05
DE69433552T2 (de) 2004-12-16
US20020010325A1 (en) 2002-01-24
DE69433552D1 (de) 2004-03-18
WO1995006065A1 (en) 1995-03-02
JPH09502174A (ja) 1997-03-04
AU7567594A (en) 1995-03-21
FI960743A (fi) 1996-02-19
US5516658A (en) 1996-05-14
ATE259377T1 (de) 2004-02-15
JP3699477B2 (ja) 2005-09-28
NO960652D0 (no) 1996-02-19
NZ271878A (en) 1997-10-24
NO960652L (no) 1996-02-19
US6949366B2 (en) 2005-09-27
KR960704038A (ko) 1996-08-31
JP2004187689A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
FI960743A0 (fi) Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin
ATE350386T1 (de) Elk ligand, ein cytokin
ATE353906T1 (de) Cd27 ligand
EP0770088A4 (en) NEW DESIGNED LERK-5 CYTOKINE
EP0871702A4 (en) CYTOKINE DESIGNED BY LERK-7
CA2312667A1 (en) Novel cytokine
DE97905729T1 (de) Als 2f1 bezeichnetes rezeptorprotein
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
DE69832178D1 (de) Trail bindender rezeptor
IL132496A0 (en) Mammalian cytokine-like factor 7
WO1998011225A3 (en) A novel haemopoietin receptor and genetic sequences encoding same
NO882054D0 (no) Sementblanding, saerlig til bruk i borehull.
NO984233L (no) Cytokin kalt lerk-8
IL138585A0 (en) Vertebrate batched -2 protein
ATE386114T1 (de) Gene, die für lymphocyte spezifischen interferon- regulationsfaktor (lsirf) polypeptide kodiert
MX9700213A (es) Citocina novedosa designada como lerk-5.
BG103627A (en) New ifn receptor 1-binding proteins, dna encoding them, and methods for the modulation of a cellular response for interferons
AU2002360392A1 (en) New gene expressed in prostate cancer and methods of use
ES1004744U (es) Verificador y saneador de culatas yno bloques de motores de explosion y superficies planas